Key Presentations at ASCO 2021 Review Primary Prevention of Prostate Cancer in African American Men

Video

CancerNetwork® sat down with Edmund Qiao at the 2021 American Society of Clinical Oncology Annual Meeting to talk about prostate-specific antigen screening and prostate cancer prevention in African American men.

At the 2021 American Society of Clinical Oncology Annual Meeting, CancerNetwork® spoke with Edmund Qiao, a fourth-year medical student from University of California San Diego and lead author of a study about prostate cancer prevention in African American men.

Given that African American men are more likely to be diagnosed with lethal prostate cancer at a younger age compared to non-Hispanic White men, the study aimed to determine interventional measures that may combat health disparities in this population. The study encompassed over 4000 men with a median age of 51.8 years and showed that increased intensity of prostate-specific antigen screening led to earlier detection and potential improvement in outcomes for younger African American men. 

Transcript:

This study emphasizes the importance of primary prevention of prostate cancer. We focus on the prostate-specific antigen screening for the basis of the presentation. One fact of our models is that we do include [primary care provider (PCP)]–utilization rates as well, [which is] basically a measure of how frequently a patient goes to the PCP. We did find that those were also significantly associated with a reduced risk of all of our end points. Taking [that] into context with the PSA screening, we feel that primary prevention of prostate cancer comes through primary care visits and just continuity of care. In terms of where [to] start, the primary prevention of prostate cancer is a very important aspect of the overall care.

References

Qiao E, Kotha N, Nalawade V, et al. Association of increased intensity of prostate-specific antigen screening in younger African American men with improved prostate cancer outcomes. J Clin Oncol. 2021;39(suppl 15):5004. doi: 10.1200/JCO.2021.39.15_suppl.5004

Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Related Content